Acessibilidade / Reportar erro
Medicina Veterinária • Ciênc. anim. bras. 15 (4) • Dez 2014 • https://doi.org/10.1590/1809-6891v15i45553   copiar

Azitromicina no tratamento da erlichiose monocítica em cães naturalmente infectados

Azithromycin in the treatment of monocytic ehrlichiosis in naturally infected dogs

Autoria SCIMAGO INSTITUTIONS RANKINGS

Resumos

Os objetivos deste trabalho foram avaliar a eficácia do tratamento com azitromicina em cães naturalmente infectados por E. canis e acompanhar a evolução clínico-hematológica dos animais. Dez cães, com diagnóstico positivo para E. canis por meio do teste de Elisa Snap 4Dx, foram distribuídos em dois grupos, sem tratamento e tratados com azitromicina, 20 mg/kg, via oral, uma vez ao dia, durante sete dias. Além do exame físico diário foram realizados hemogramas, esfregaços de ponta de orelha para a pesquisa de mórulas e nested PCR antes do tratamento e pós-tratamento. Verificou-se que o tratamento não foi eficiente, uma vez que não desapareceram os sinais clínicos, assim como não houve retorno à normalidade dos valores do hemograma nos cães, assim como ausência de eliminação de E. canis.

Azitromicina; Ehrlichia canis; PCR; Cães

The aims of this study were to evaluate the effectiveness of treatment with azithromycin in dogs naturally infected with E. canis, and to analyse the clinical and hematological changes the animals would show. Ten dogs with positive diagnosis for E. canis through Elisa Snap 4Dx test were distributed into two groups, untreated and treated with azithromycin, 20 mg/kg, orally once a day for seven days. In addition to the physical exam, complete blood counts (CBC), smears made out from blood of the ear margin in order to detect ehrlichial morulae and nested PCR before treatment and post-treatment were performed. We found that the treatment was not effective, since the clinical signs did not disappear, as well as there was no return to normal values of the CBC in treated animas, neither the elimination of E. canis from the infected animals.

azithromycin; Ehrlichia canis; PCR; Dogs

  • 1
    Harrus S, Waner T, Aizenberg I, Bark H. Therapeutic effect of doxycycline in experimental subclinical canine monocytic ehrlichiosis: evaluation of a 6-week course. Journal of Clinical Microbiology.1998b;36(7):2140-2142.
  • 2
    Dantas-Torres, F. The brown dog tick, Rhipicephalus sanguineus (Latreille, 1806) (Acari: Ixodidae): From taxonomy to control. Veterinary Parasitology. 2008; 152 (3-4):173-185.
  • 3
    Vieira RF Da C, Biondo AW, Guimarães MAS, Santos AP, Santos RP, Dutra LH, Diniz P PVP, Morais HA, Messick JB, Labruna MB, Vidotto O. Ehrlichiosis in Brazil. Revista Brasileira de Parasitologia Veterinária, Jaboticabal. 2011;20(1):1-12, jan-mar.
  • 4
    Trapp SM, Dagnone AS, Vidotto O, Freire RL, Amude AM, Morais HS. Seroepidemiology of canine babesiosis and ehrlichiosis in a hospital population. Vet Parasitol. 2006;140: 223-230.
  • 5
    Labarthe N, De Campos Pereira M, Barbarini O, Mckee W, Coimbra CA, Hoskins J. Serologic prevalence of Dirofilaria immitis, Ehrlichia canis and Borrelia burgdorferi infections in Brazil. Veterinary Therapeutics.2003;4(1):67-75.
  • 6
    Vieira TSWJ, Vieira RFC, Nascimento DAG, Tamekuni K, Toledo RS, Chandrashekar R, Marcondes M, Biondo AW, Vidotto O. Serosurvey of tick-borne pathogens in dogs from urban and rural areas from Paraná State, Brazil. Revista Brasileira de Parasitologia Veterinária. 2013; 22(1):104-109.
  • 7
    Rudoler N, Baneth G, Eyal O, Van Straten M, Harrus S. Evaluation of an attenuated strain of Ehrlichia canis as a vaccine for canine monocytic ehrlichiosis. Vaccine. 2012; 31: 226-233.
  • 8
    Breitschwerdt EB, Hegarty BC, Hancock SI. Doxycycline hyclate treatment of experimental canine ehrlichiosis followed by challenge inoculation with two Ehrlichia canis strains. Antimicrobial Agents and Chemotherapy. 1998; 42(2):362-368
  • 9
    McClure JC, Crothers ML, Schaefer JJ, Stanley PD, Needham GR, Ewing SA, Stich RW. Efficacy of a Doxycycline Treatment Regimen Initiated during Three Different Phases of Experimental Ehrlichiosis. Antimicrobial Agents And Chemotherapy, 2010, p. 5012–5020.
  • 10
    Schaefer JJ, Needham GR, Bremer WG, Rikihisa Y, Ewing SA, Stich RW. Tick acquisition of Ehrlichia canis from dogs treated with doxycycline hyclate. Antimicrobial Agents and Chemotherapy. 2007 (51):3394–3396.
  • 11
    Neer TM, Breitschwerdt EB, Greene RT, Lappin MR. Consensus statement on ehrlichial disease of small animals from the infectious disease study group of the ACVIM. Journal of Veterinary Internal Medicine. 2002; 16(3):309-315.
  • 12
    Wen B, Rikihisa Y, Mott JM, Greene R, Kim HY, Zhi N, Couto GC, Unver A, Bartsch R. Comparison of nested PCR with Immunofluorescent -antibody Assay for detection of Ehrlichia canis infection in dogs treated with doxycycline. Journal of Clinical Microbiology. 1997;35(7):1852-1855.
  • 13
    Theodorou K, Mylonakis ME, Siarkou VI, Leontides L, Koutinas AF, Koutinas CK, Kritsepi-Konstantinou M, Batzias G, Flouraki E, Eyal O,Vassilios K, Harrus S. Efficacy of rifampicin in the treatment of experimental acute canine monocytic ehrlichiosis. Journal Antimicrob Chemother. 2013; 68: 1619 –1626.
  • 14
    Girard AE, Girard D, English AR, Gootz TD, Cimochowski CR, Faiella JA, Haskell SL, Retsema JA. Pharmacokinetics and in vivo studies with azithromycin (CP-62.993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrobial Agents and Chemotherapy. 1987; 31:1948-1954.
  • 15
    Zur G, Soback S, Weiss Y, Perry E, Lavy E, Britzi M. Azithromycin pharmacokinetics in the serum and its distribution to the skin in healthy dogs and dogs with pyoderma. The Veterinary Journal. 2014; 200:122-126.
  • 16
    Di Cicco MF, Downey ME, Beeler E, Marr H, Cyrog P, Kidd L, Diniz PP, Cohn LA, Birkenheuer AJ. Re-emergence of Babesia conradae and effective treatment of infected dogs with atovaquone and azithromycin. Vet Parasitol. 2012 8;187(1-2):23-27.
  • 17
    Sakuma M, Setoguchi A, Endo Y. Possible Emergence of Drug-Resistant Variants of Babesia gibsoni in Clinical Cases Treated with Atovaquone and Azithromycin. Journal of Veterinary Internal Medicine. 2009; 23(3): 493-498.
  • 18
    Yagci BB, Uralt K, Ocal N, Haydardedeoglu AE. Azithromycin therapy of papillomatosis in dog: a prospective, randomized, double-blinded, placebo-controlled clinical trial. Vet Dermatol. 2008; 19:194-198.
  • 19
    Schwab JC, Mandell GL. The importance of penetration of antimicrobial agents into cells. Infectious Disease Clinics of North America. 1989;3:461-467.
  • 20
    Glaudue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62.993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrobial Agents and Chemotherapy. 1989;33:277-282.
  • 21
    Wildfewer A, Laufen G, Muller-Wening D, Haferkamp O. Interaction of azithromycin and human phagocytic cells. Uptake of the antibiotic and the effect on the survival of ingested bacteria. Arzneimittel-Forschung. 1989;39:755-758.
  • 22
    Watt G, Kantipong P, Jongsakul K, Watcharapichat P, Phulsuksombati D. Azithromycin Activities against Orientia tsutsugamushi Strains Isolated in Cases of Scrub Typhus in Northern Thailand. Antimicrobial Agents and Chemotherapy. 1999; 43(11):2817-2818.
  • 23
    Phimda K, Hoontrakul S, Suttinont C, Chareonwat S, Losuwanaluk K, Chueasuwanchai S, Chierakul W, Suwancharoen D, Silpasakorn S, Saisongkorh W, Peacock SJ, Day NPJ, Suputtamongkol Y. Doxycycline versus Azithromycin for treatment of Leptospirosis and Scrub Typhus. Antimicrobial Agents and Chemotherapy. 2007;51(9):3259-3263.
  • 24
    Krolewiecki A, Leon S, Scott P, Abraham D. Activity of azithromycin against Leishmania major in vitro and in vivo American Journal of Tropical Medicine and Hygiene. 2002; 67(3):273-277.
  • 25
    Zhou CM, Hu BJ, Gao XD, Bao R, Xie HM, Huang SL, Tao LL, He LX. Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from patients in primary hospitals in Shanghai from 2007 to 2010. Zhonghua Jie He He Hu Xi Za Zhi. 2013; 36(5):346-50.
  • 26
    Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sexually Transmitted Diseases. 2002; Sep; 29(9):497-502.
  • 27
    Pechére JC. The Activity of Azithromycin in Animal Models of Infection. Eur. J. Clin. Microbiol. Dis. 1991; 10(10):821-827.
  • 28
    Kaneko JJ, Harvey JW, Bruss ML. Clinical biochemistry of domestic animals. 5th ed. San Diego: Academic Press. 1997; 932. English.
  • 29
    Bulla C, Takahira RK, Araújo Jr JP, Trinca LA, Lopes RS, Wiedmeyer CE. The relationship between the degree of thrombocytopenia and infection with Ehrlichia canis in an endemic area. Veterinary Research. 2004;35(1):141-146.
  • 30
    Kuehn NF, Gaunt SD. Clinical and hematologic findings in canine ehrlichiosis. Journal of the American Veterinary Medical Association. 1985;186(4):355-358.
  • 31
    Moreira SM, Bastos CV, Araújo RB, Santos M, Passos LMF. Estudo retrospectivo (1998 a 2001) da erliquiose canina em Belo Horizonte. Arquivo Brasileiro de Medicina Veterinária Zootecnia. 2003; 55:141-147.
  • 32
    Elias E. Diagnosis of ehrlichiosis from the presence of inclusion bodies or morulae of E. canis Journal of Small Animal Practice. 1991;33(11):540-543.
  • 33
    Harrus, S.; Waner, T. Diagnosis of canine monocytotropic ehrlichiosis (Ehrlichia canis): An overview. The Veterinary Journal. 2011; 187: 292–296.
  • 34
    Buhles WC, Huxsoll DL, Ristic M. Tropical canine pancytopenia: clinical, hematologic and serologic response of dogs to Ehrlichia canis infection, tetracycline therapy, and challenge inoculation. Journal of Infectious Diseases. 1974;130:357-367.
  • 35
    Waner T, Leykin I, Shinitsky M, Sharabani E, Buch H, Keysary A, Bark H, Harrus S. Detection of platelet-bound antibodies in beagle dogs after artificial infection with Ehrlichia canis Veterinary Immunology Immunopathology. 2000;77:145-150.
  • 36
    Castro MB, Machado RZ, Aquino LPCT, Alessi AC, Costa MT. Experimental acute canine monocytic ehrlichiosis: clinicopathological and immunological findings. Veterinary Parasitology. 2004;119:73-86.
  • 37
    Sousa MG, Higa AC, Gerardi DG, Tinucci-Costa M, Machado R. Tratamento da erlichiose canina de ocorrência natural com doxiciclina, precedida ou não pelo dipropionato de imidocarb. Revista de Ciências Agroveterinárias. 2004; 3:126-130.
  • 38
    Harrus S, Kenny M, Miara L, Aizenberg I, Waner T, Shaw S. Comparison of simultaneous splenic sample PCR with blood sample PCR for diagnosis and treatment of experimental Ehrlichia canis infection. Antimicrobial Agents Chemother. 2004; 48: 4488-4490.
  • 39
    Faria JLM, Dagnone AS, Munhoz TD, João CF, Pereira WAB, Machado RZ, Tinucci-Costa M. Ehrlichia canis morulae and DNA detection in whole blood and spleen aspiration samples. Revista Brasileira de Parasitologia Veterinária. 2010; 19(2): 98-102.

Datas de Publicação

  • Publicação nesta coleção
    22 Jan 2015
  • Data do Fascículo
    Dez 2014

Histórico

  • Aceito
    13 Maio 2014
  • Recebido
    13 Fev 2009
Creative Common - by 4.0
This work is licensed under a Creative Commons Attribution 4.0 International License.
Universidade Federal de Goiás Universidade Federal de Goiás, Escola de Veterinária e Zootecnia, Campus II, Caixa Postal 131, CEP: 74001-970, Tel.: (55 62) 3521-1568, Fax: (55 62) 3521-1566 - Goiânia - GO - Brazil
E-mail: revistacab@gmail.com
Acompanhe os números deste periódico no seu leitor de RSS